Dr. Nilay Arvind Shah, MD

Dr. Shah practices at Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health.

Dr. Shah's NPI, 1356541445, was assigned on July 18, 2007. Dr. Shah holds North Carolina license 2019-00170.

Dr. Shah's primary practice is Atrium Health Carolinas Medical Center, at 1000 Blythe Blvd, Charlotte, NC 28203 in Mecklenburg County. The practice phone is (704) 355-2000.

Dr. Shah's primary practice is Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health. Dr. Shah is also affiliated with Atrium Health Wake Forest Baptist Medical Center. The medical group on file is Atrium Health Levine Cancer Institute. Dmand AI also links Dr. Shah to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shah practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Shah's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Shah is licensed in North Carolina.

CMS data shows 154 Medicare services from Dr. Shah across 1 procedure code in 2024, all of them office visits, for 59 Medicare patients. Medicare paid $15,095 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 59 Medicare patients who saw Dr. Shah in 2024. The largest group is 65 to 74, with 24 patients. 71% of them have high cholesterol, and 68% have high blood pressure. Their average risk score is 2.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shah's median patient age at 71, with 52% women.

In 2024, Dr. Shah wrote 386 Medicare Part D claims for 49 patients. 62% of them were for generic drugs. CMS names the drug for 276 of them, across 12 drugs with 11 or more claims each, at $1,538,523 in total drug cost. In 2023, CMS named 109 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Shah for performance year 2024, reported as part of a group. Dr. Shah accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Shah, published from 2022 to 2024. 2022 was the busiest year, with 3. Dr. Shah's most frequent co-authors are Jing Ai, MD, Aleksander Lech Chojecki, MD and Michael Richard Grunwald, MD.

Dmand AI links Dr. Shah to 1 clinical trial. Conditions studied include Leukemia, Myeloid, Acute and Leukemia, Myeloid.

CMS Open Payments shows 226 general payments to Dr. Shah from 14 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 86% of the total. Incyte Corporation paid the most, $152,399.